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Motivation and Objective
Tumors develop resistance to numerous drug therapies, and this remains a major obstacle in treating 
many types of non-surgical cancers. Melanoma provides a good model system for studying drug 
resistance in cancer due to its high propensity to incur resistance after a significant initial response to 
a drug. Genes that are highly expressed in melanoma cancer cells have been studied, but in order to 
further understand the collective function of these highly expressed genes we must analyze gene 
sets, or pathways. A single gene’s function is rarely independent of other genes, and pathway analysis 
takes this into account. 
Our objective is to simplify single-cell RNA sequence data to model pathways and pinpoint which 
unique pathways are up-regulated and down-regulated in drug resistant and nonresistant melanoma 
cell phenotypes. Identifying these important pathways provides a more accurate depiction of 
melanoma heterogeneity and informs us of the pathways that are likely to be effective targets for 
new drug therapies, bringing us closer to overcoming drug-induced resistance.
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More than half of melanoma patients have a driver mutation in the BRAF 
protein, and an inhibitor that targets the mutated BRAF protein leads to 
significant initial response in these patients. Despite this initial response, 
the tumors always come back, indicating that tumor cells have also 
developed resistance to the BRAF inhibitor.
During BRAF inhibitor treatment,  
melanoma cells will transition from 
the original melanocytic, drug 
sensitive cancer cell phenotype 
towards a stem-like drug-resistant 
cancer cell phenotype. This process 
is called Melanocyte to Neural-crest 
Transition (MNT), and this process 
causes non-genetic resistance to the 
BRAF inhibitor drug.
Melanoma cells are not homogeneous, and we found 
four unique subpopulations in our day 24 melanoma 
cells (shown on the plot at right). Three of the four 
clusters are known phenotypes of melanoma cells: drug-
sensitive melanocytic cells, drug tolerant neural-crest 
cells, and drug-resistant mesenchymal cells. Researchers 
also found a novel resistant cluster of cells, seen in blue 
on the plot at right. Identifying the important pathways 
in both resistant clusters, especially the previously 
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Results: Pathway Analysis of Day 24 Melanoma Cells
Differentially Expressed Pathways between Resistant 
and Nonresistant Melanoma Cell Clusters
Research Question:
• What do the patterns of pathway expression for known resistant 
subpopulations of melanoma cells tell us about the cell-state transitions that 
lead to drug-induced resistance?
Approach:
• Identify unique pathways for each subpopulation using Gene Set Expression 
Analysis (GSEA) and calculate the levels of pathway expression (upregulation 
or downregulation) for each cell using Gene Set Variation Analysis (GSVA).
• Visually represent pathway relationships using Cytoscape, an open source 
software platform for visualizing molecular interaction networks and 
biological pathways.
• Visually represent how pathway expression changes over time after exposure 
to a BRAF inhibitor drug with trajectory analysis of single-cell RNA sequence 
data combined with pathway scores obtained from GSVA analysis.
Melanoma Subpopulations: day 24
• Model the emergence of heterogeneity over time in important pathways. 
• How does gene expression change over time with exposure to BRAFi in these pathways?
Emergence of Melanoma Heterogeneity through Time: Expression of Marker Genes:
• Transpose pathway score data calculated from GSVA onto single-cell RNA sequence 
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Mesenchymal Marker Pathway
Cytoscape Model: Differentially Expressed 
Pathways between Resistant and Nonresistant 
Melanoma Cell Clusters
Pathway Scores of Notable Pathways Transposed onto Single-cell RNA-seq Trajectory 
Melanoma Cell Subpopulation Locations:
Surprisal Analysis:
• We are planning to use surprisal analysis, a method derived from physical chemistry, to cluster our 
cells and find new modules of coregulated genes that differentiate our novel cluster from the 
other resistant and nonresistant subpopulations.
• We will use Cytoscape to visually represent pathways of interest
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